Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[161Tb]Tb-J3-7D12-Fc
- Development stage
- Preclinical
- Lead developer
- BC Cancer Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[161Tb]Tb-J3-7D12-Fc is a novel interleukin-1 receptor accessory protein (IL1RAP)-targeted radioimmunoconjugate being developed for the treatment of Ewing sarcoma (EwS). It consists of the antibody fragment 7D12-Fc, which targets IL1RAP, conjugated via the crown-ether-derived chelator J3 to the beta- and Auger-emitting radioisotope terbium-161 ([161Tb]Tb3+). IL1RAP is highly overexpressed on the surface of Ewing sarcoma cells compared to healthy tissues, making it a promising therapeutic target. The J3 chelator allows for conjugation and radiolabeling under mild, room-temperature conditions, preserving the integrity of the thermolabile antibody fragment. Preclinical studies have demonstrated that [161Tb]Tb-J3-7D12-Fc exhibits high binding affinity, specificity, and significant tumor accumulation in vivo, with ongoing studies evaluating its therapeutic efficacy in tumor-bearing murine models.
- Other names
- [161Tb]Tb-J3-7D12 Fc161Tb-J3-7D12 Fc161Tb-J3-7D12-Fc
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on [161Tb]Tb-J3-7D12-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [161Tb]Tb-J3-7D12-Fc.